Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Dual agonist peptide
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
GLP-1 and glucagon receptor agonism.
Evidence and critical reading
Reported scientific and empirical uses
Reported glycemic control · Reported weight management
Dual GLP-1/glucagon agonist with documented NMPA approval of a specific product.
Human evidence
GLORY-2 randomized phase 3 trial in Chinese adults reported clinically meaningful weight loss. Population and formulation matter.
Preclinical evidence
Do not confuse with GLP-2 agonism or retatrutide.
Critical reading and limitations
GLORY-2 is human evidence; it does not make every internationally sold vial equivalent to the authorized Chinese product.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.
9 mg · Target maintenance amount; not a starting amount
- Frequency
- Weekly
- Duration
- 60 weeks
- Route
- Subcutaneous
- Context
- GLORY-2: 462 randomized, 461 treated, Chinese adults with obesity. Not equivalent to every China-approved dose.
- Presentation
- A dosage-form presentation is not specified in the reviewed record.
- Interpretation
- Research exposure: not a prescription or starting regimen. It does not reconstruct protocol titration, exclusions or monitoring.
PMID42251595 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Empirical handbook
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Regulation and safety
Jurisdiction-specific regulatory context
China: NMPA records approval of mazdutide injection on 24 June 2025; verify exact approved product and indication separately. US/EU status not established in this card.
Adverse effects and unknowns
Gastrointestinal adverse reactions reported; approval and safety cannot be transferred to an unidentified catalog product.
GI events predominate in the trial; verify exact jurisdiction/indication before asserting authorization.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
NCT06164873 · A Study of IBI362 9 mg in Chinese Adults With ObesityRegistry status: UnknownLast update posted: August 27, 2024Query verification: October 16, 2026
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Mazdutide · 43 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT07657676 · Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or ObesityRegistry status: RecruitingLast update posted: October 13, 2026Query verification: October 16, 2026
NCT06143956 · A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightRegistry status: RecruitingLast update posted: October 7, 2026Query verification: October 16, 2026
NCT07843862 · A Study of HRS-4729 Injection in Participants With Type 2 DiabetesRegistry status: Not yet recruitingLast update posted: September 28, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID42251595
Gao L, Jiang H, Cai H, Tian J, Shi B, Qiu W, Huang C, Han J, Zhang S, Pang S, Bi Y, Chen L, Gu X, Han J, Ma Q, Deng H, Wang Y, Li L, Han-Zhang H, Qian L, Ji L, GLORY-2 Trial Investigators.
October 16, 2026
- REG-MAZ
NMPA mazdutide approval notice, 24 June 2025
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026